Lilly builds China Medical Innovation Center and Innovation Incubator in Beijing
守遍丝
发表于 2024-10-16 11:04:33
1221
0
0
On October 15th, Lilly announced the establishment of the China Medical Innovation Center in Beijing and plans to set up Lilly Gateway Labs (LGL) to promote clinical research and accelerate drug development.
It is reported that the Lilly China Medical Innovation Center, located in Beijing, is a cutting-edge research center dedicated to improving clinical trial efficiency, supporting drug registration and evaluation, and aiming to accelerate the benefit of innovative drugs to patients. Relying on the profound clinical medical resources in Beijing, the center will integrate advanced technological means and innovative models, optimize real-world data and analysis, and promote the high-quality development of medical research.
At the same time, Lilly announced plans to introduce its innovation incubator (Lilly Gateway Labs, LGL) to China. As a leading innovation platform in the industry, Lilly Innovation Incubator is committed to identifying and supporting high potential biotechnology companies in the early stages of research and development. By integrating Lilly's professional technical resources, LGL will help the next generation of scientific innovation breakthroughs, and this investment marks the company's first expansion of Lilly's innovation incubator beyond the United States.
Daniel Skovronsky, Chief Scientific Officer of Eli Lilly, President of Eli Lilly Research Laboratory, and President of Eli Lilly Immunotherapy, stated that the establishment of Eli Lilly China Medical Innovation Center and Eli Lilly Innovation Incubator in Beijing will further deepen Eli Lilly's century long business layout in China. The new center will empower the exploration of novel clinical research designs to accelerate patients' access to breakthrough therapies. The Lilly Innovation Incubator will provide office space and research strategy guidance for domestic start-up biotechnology companies, helping them develop new generation drugs for patients.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
-
アップル(AAPL)は現地時間10月31日、9月28日までの2024年第4四半期の業績を発表し、同四半期の売上高は前年同期比6%増の949億3000万ドル、純利益は同36%減の147億3600万ドルだった。 純利益の下落は主に102億ドル ...
- 亲亲宝宝贝贝贾
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 昨天 17:54
- 支持
- 反对
- 回复
- 收藏
-
【147億ドル!米大統領選はどれほど「お金を燃やす」のか?】米大統領選はかねてから「お金」と結びついており、総選挙が秒読みに入るにつれ、今年の大統領選は米国史上最も高価なものになる見込みだ。ブルームバー ...
- hecgdge4
- 昨天 10:54
- 支持
- 反对
- 回复
- 收藏
-
「エクソダス」バフェット傘下のバークシャー社が最新発表した3季報によると、2024年9月30日現在、バークシャーの現金準備高は記録的な3252億ドル(約2兆3000億元)に達し、9四半期連続で上昇し、2年前に比べて約22 ...
- hecgdge4
- 昨天 19:39
- 支持
- 反对
- 回复
- 收藏